| 06/10/26 | 07:00:02 | 6 Oct 2026 | | Results of Placing and Subscription | RNS |
| 05/10/26 | 16:22:58 | 5 Oct 2026 | | Proposed Fundraise to raise approximately £12.5m | RNS |
| 30/09/26 | 13:00:00 | 30 Sept 2026 | | Interim Results for the Six Months to June 30, 2026, and Business Update | GNW |
| 30/09/26 | 07:01:00 | 30 Sept 2026 | | Capital Access Window | RNS |
| 30/09/26 | 07:00:06 | 30 Sept 2026 | | Interim Results for Six Months to June 30, 2026 | RNS |
| 25/09/26 | 08:00:00 | 25 Sept 2026 | | pre|CISION® Platform Wins R&D Achievement Award | RNS |
| 25/09/26 | 07:00:07 | 25 Sept 2026 | | Further Demonstration of Potential of AVA6103 | RNS |
| 25/09/26 | 07:00:00 | 25 Sept 2026 | | The FOCUS-01 Clinical Trial Design and Preclinical Data Further Demonstrate the Potential of AVA6103 at AACR Conference on Pancreatic Cancer | GNW |
| 16/09/26 | 16:00:00 | 16 Sept 2026 | | Avacta Achieves Clinical Proof of Mechanism for the Next Generation of pre|CISION® Medicines with AVA6103 (FAP-Exd) in the Phase 1 FOCUS-01 Trial | GNW |
| 16/09/26 | 07:00:04 | 16 Sept 2026 | | Clinical Proof of Mechanism for preCISION Platform | RNS |
| 14/09/26 | 07:00:10 | 14 Sept 2026 | | Mats Blom to Board as Chair of Audit Committee | RNS |
| 14/09/26 | 07:00:00 | 14 Sept 2026 | | Avacta Appoints Mats Blom to the Board of Directors as Chair of Audit Committee | GNW |
| 04/09/26 | 07:00:03 | 4 Sept 2026 | | Accelerated Payment Convertible Bond Installment | RNS |
| 01/09/26 | 07:00:15 | 1 Sept 2026 | | Share Option Awards to Management Team at Avacta | RNS |
| 09/07/26 | 07:00:04 | 9 Jul 2026 | | Accelerated Amortized Payment of Bond Installment | RNS |
| 08/07/26 | 07:00:04 | 8 Jul 2026 | | Avacta Appoints Patrick Vink Deputy Chairman | RNS |
| 08/07/26 | 07:00:00 | 8 Jul 2026 | | Avacta Appoints Healthcare Executive Patrick Vink as Deputy Chairman of the Board of Directors | GNW |
| 25/06/26 | 07:00:04 | 25 Jun 2026 | | Platform-Validating Data with Faridoxorubicin | RNS |
| 25/06/26 | 07:00:04 | 25 Jun 2026 | | FDA Agreement on Pivotal Trial Design for AVA6000 | RNS |
| 23/06/26 | 07:00:03 | 23 Jun 2026 | | Result of AGM | RNS |
| 22/06/26 | 07:00:08 | 22 Jun 2026 | | Year-to-date business update ahead of AGM | RNS |
| 05/06/26 | 07:00:02 | 5 Jun 2026 | | Oversubscribed Strategic Equity Fundraise of £9m | RNS |
| 01/06/26 | 15:00:00 | 1 Jun 2026 | | Block Listing - Application to AIM | RNS |
| 01/06/26 | 07:00:09 | 1 Jun 2026 | | Clinical data on AVA6000 in salivary gland cancers | RNS |
| 01/06/26 | 07:00:00 | 1 Jun 2026 | | Avacta presents updated clinical data showing encouraging early efficacy signals for AVA6000 in salivary gland cancers at ASCO 2026 | GNW |
| 29/05/26 | 07:00:05 | 29 May 2026 | | Posting of Annual Report and Notice of AGM | RNS |
| 29/05/26 | 07:00:04 | 29 May 2026 | | Board Director Changes | RNS |
| 19/05/26 | 07:14:00 | 19 May 2026 | | Unaudited Preliminary Results for the Year Ended December 31, 2025 | GNW |
| 19/05/26 | 07:00:08 | 19 May 2026 | | Unaudited Preliminary Full Year 2025 Results | RNS |
| 13/05/26 | 07:00:06 | 13 May 2026 | | Notice of Preliminary Results and Presentation | RNS |
| 13/05/26 | 07:00:03 | 13 May 2026 | | Issue of Equity and Total Voting Rights | RNS |
| 06/05/26 | 07:00:04 | 6 May 2026 | | Pre|CISION® payload release vs approved ADCs | RNS |
| 06/05/26 | 07:00:00 | 6 May 2026 | | Avacta presents new comparisons of pre|CISION® payload release vs approved ADCs and AVA6207 dual payload delivery at Science Day 2026 | GNW |
| 28/04/26 | 07:00:11 | 28 Apr 2026 | | Block Listing Six Monthly Return | RNS |
| 21/04/26 | 17:00:00 | 21 Apr 2026 | | Avacta data at AACR 2026 underline favorable profile of AVA6103 and advantages of pre|CISION® delivery platform | GNW |
| 21/04/26 | 07:00:06 | 21 Apr 2026 | | Avacta data AACR underline AVA6103 profile | RNS |
| 14/04/26 | 11:37:07 | 14 Apr 2026 | | Christina Coughlin - In Vivo 2026 Rising Leader | RNS |
| 09/04/26 | 07:00:05 | 9 Apr 2026 | | Q1 2026 Business Update | RNS |
| 08/04/26 | 07:00:09 | 8 Apr 2026 | | Avacta Announces Science Day 2026 | RNS |
| 31/03/26 | 07:00:10 | 31 Mar 2026 | | First patient treated in Phase 1 trial of AVA6103 | RNS |
| 27/03/26 | 07:00:04 | 27 Mar 2026 | | Result of Oversubscribed Fundraise | RNS |
| 26/03/26 | 17:16:49 | 26 Mar 2026 | | Proposed Fundraise to raise approximately £10m | RNS |
| 26/03/26 | 16:44:56 | 26 Mar 2026 | | Issue of Equity | RNS |
| 17/03/26 | 07:00:15 | 17 Mar 2026 | | Presentations of pre|CISION® Platform Candidates | RNS |
| 16/03/26 | 07:00:10 | 16 Mar 2026 | | Phase 1 study opening for AVA6103 | RNS |
| 24/02/26 | 07:00:07 | 24 Feb 2026 | | PreCISION payload delivery advantage over ADC | RNS |
| 18/02/26 | 07:00:07 | 18 Feb 2026 | | Avacta to Participate in Conference March 2026 | RNS |
| 09/02/26 | 07:00:07 | 9 Feb 2026 | | Appointment of CSO | RNS |
| 03/02/26 | 07:00:10 | 3 Feb 2026 | | Faridoxorubicin Program Clinical Updates | RNS |
| 21/01/26 | 07:00:08 | 21 Jan 2026 | | FDA Clearance of IND Application for AVA6103 | RNS |
